GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LN-145 overview

LN-145 is under development for the treatment of metastatic melanoma, metastatic triple negative breast cancer, soft tissue sarcoma, osteosarcoma, bone sarcoma, chondrosarcoma, giant cell tumor of bone, anaplastic thyroid cancer, ovarian cancer, cervical cancer, head and neck squamous cell carcinoma, advanced or metastatic non-small cell lung cancer (NSCLC), primary central nervous system carcinoma, rhabdomyosarcoma, dedifferentiated sarcoma and Ewing sarcoma. The therapeutic candidate is administered as intravenous route. It constitutes of tumor infiltrating lymphocytes (TILs) isolated from the patient’s tumor further expanded and then infused back to the patient enabling patient robust immune response. It is being developed based on TIL platform.

It was under development for the treatment of metastatic transitional cell cancer of the urothelium including renal pelvis cancer, ureters cancer, urinary bladder cancer and urethra cancer and refractory HPV-associated cancer.

Iovance Biotherapeutics overview

Iovance Biotherapeutics (Iovance) is a biopharmaceutical company. It focuses on the development and commercialization of novel immunotherapy products for treating various cancers. It develops products based on its tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidates include Amtagvi (lifileucel), an autologous, ready-to-infuse cell therapy indicated for the treatment of melanoma and metastatic cervical cancer and Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen. The company also investigates TIL therapy for treating various types of cancers. It operates a manufacturing facility in Philadelphia and a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.

For a complete picture of LN-145’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.